Sasine Highlights Strides With CAR T-Cell Therapy in Hematologic Cancers

Joshua P. Sasine, MD, PhD

The reach of CAR T-cell therapy is expanding, explained Joshua P. Sasine, MD, PhD, and with each additional analysis, the field of hematologic oncology is learning how to maximize the safety and efficacy of each emergent product.

“Now we have longer follow-up from the original clinical trials that continues to show the benefit patients are experiencing from the treatment,” said Sasine. “We are also learning more about how to use these products, including how to make them safer and [we’re getting better at being able to] predict who and when patients will derive the most benefit.”

Currently, there are 2 FDA-approved CD19-directed CAR T-cell therapies, axicabtagene ciloleucel (axi-cel; Yescarta) and tisagenlecleucel (Kymriah), which have both demonstrated encouraging clinical activity.